An Unpopular Pick: 5 Reasons Why Buying UnitedHealth Group Stock Now Could Be a Brilliant Move

UnitedHealth Group (UNH) is navigating significant challenges, including a DOJ investigation into Medicare billing, rising medical costs impacting its Medicare Advantage plans, and a nearly 60% stock decline from its late 2024 peak, leading to a disappointing Q2 2025 update and reduced full-year earnings expectations. In response, the company plans premium increases for 2026, aggressive cost-cutting measures targeting $1 billion in savings from Optum Health by 2026, and operational streamlining. Despite near-term headwinds, the article asserts UNH's long-term growth prospects remain strong, with earnings projected to rebound in 2026 and accelerate thereafter, positioning the stock as a potential bargain at a forward P/E below 11.6, particularly with the return of former CEO Stephen Hemsley.

Analysis

UnitedHealth Group (UNH) is navigating significant operational and legal challenges, reflected in a disappointing Q2 2025 update, lowered full-year earnings guidance, and a stock price decline of nearly 60% from its late 2024 peak. The primary headwinds include a U.S. Department of Justice investigation into its Medicare billing practices and higher-than-anticipated medical costs impacting its Medicare Advantage plans. In response, management has outlined a clear turnaround strategy focused on raising premiums in 2026, enhancing payment integrity tools, and streamlining provider networks. Furthermore, the company is pursuing aggressive cost-cutting initiatives, including a target of nearly $1 billion in savings from its Optum Health segment by 2026 and scaling the use of AI in operations. Despite these near-term pressures, the stock trades at a historically low forward price-to-earnings ratio of below 11.6. With former CEO Stephen Hemsley returning to lead the company, management projects a return to earnings growth in 2026, with an acceleration expected in 2027 and beyond, a sentiment supported by analyst consensus.

Key Decisions for Investors

• Given the stock's significant price depreciation and a forward P/E ratio below 11.6, investors with a higher risk tolerance might view the current valuation as an attractive entry point for a long-term turnaround play.
• It is crucial to monitor developments related to the Department of Justice investigation, as any adverse findings could represent a significant catalyst and materially impact the company's financial outlook.
• Investors should closely track the execution of the company's cost-cutting programs and the successful implementation of premium increases in 2026, as these are the primary drivers for the forecasted return to earnings growth.